Toby M Maher, Cristina Avram, Enoch Bortey, Simon P Hart, Nikhil Hirani, Philip L Molyneux, Joanna C Porter, Jaclyn A Smith, Thomas Sciascia
Nalbuphine for Cough with Idiopathic Pulmonary FibrosisIn patients with idiopathic pulmonary fibrosis, cough may have a negative impact on daily life. In a randomized, 22-day treatment period, placebo-controlled, crossover trial, extended-release nalbuphine (NAL ER), an opioid agonist-antagonist, was compared to placebo for cough control and adverse effects. During active treatment there was a 75.1% reduction in daytime objective cough frequency compared with 22.6% in the placebo treatment period. Nausea, fatigue, constipation, and dizziness were more common with NAL ER than with placebo...
August 2023: NEJM Evid